Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database

Am J Cardiol. 1998 Aug 1;82(3):265-71. doi: 10.1016/s0002-9149(98)00336-1.

Abstract

Primary ventricular fibrillation (VF) complicating acute myocardial infarction (MI) predicts short-term mortality. The broad category of patients with primary VF might include subgroups with different outcomes. It is still not certain whether early-onset (< or =4 hours) primary VF is a risk predictor, and information on correlates of these early fibrillations is scarce. This study sought to prospectively analyze the incidence and prognosis of early, as opposed to late (time window >4 to 48 hours) primary VF and retrospectively identify predisposing factors for early-onset primary VF. We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial. The independent prognostic significance of early and late primary VF was assessed by logistic regression analysis. The incidence rates of early and late primary VF were 3.1% and 0.6%, respectively; recurrence rates were 11% and 15%, respectively. The 2 variables most closely related to early primary VF were hypokalemia and systolic blood pressure < 120 mm Hg on admission. Patients with early primary VF had a more complicated in-hospital course than matched controls. Both early (odds ratio [OR] 2.47, 95% confidence interval [CI] 1.48 to 4.13) and late primary VF (OR 3.97, 95% CI 1.51 to 10.48) were independent predictors of in-hospital mortality. Postdischarge to 6-month death rates were similar for both primary VF subgroups and controls. Primary VF, irrespective of its timing, was an independent predictor of in-hospital mortality. Postdischarge to 6-month prognosis was unaffected by the occurrence of either early or late primary VF.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Anti-Arrhythmia Agents / administration & dosage
  • Anti-Arrhythmia Agents / therapeutic use
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Atenolol / administration & dosage
  • Atenolol / therapeutic use
  • Drug Administration Routes
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / therapeutic use
  • Hospital Mortality
  • Humans
  • Incidence
  • Italy / epidemiology
  • Lidocaine / administration & dosage
  • Lidocaine / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Infarction / complications*
  • Myocardial Infarction / drug therapy
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Recurrence
  • Registries
  • Retrospective Studies
  • Survival Rate
  • Ventricular Fibrillation / drug therapy
  • Ventricular Fibrillation / epidemiology*
  • Ventricular Fibrillation / etiology

Substances

  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Atenolol
  • Heparin
  • Lidocaine
  • Aspirin